Psyadon Pharmaceuticals Inc.
Treating Tourette syndrome with a neuronal inhibitor
This article was originally published in Start Up
No new drug has been developed for Tourette syndrome in more than 20 years. Almost all medications prescribed for the condition are given off-label, and none are particularly effective. News reported by Psyadon Pharmaceuticals Inc. in late July 2012 is encouraging to both the patient community and the start-up itself. Psyadon announced that an open-label Phase II study of its candidate ecopipam, which inhibits dopamine via the D1 receptor, was stopped after a planned interim data analysis because the data were strong enough to suggest the compound is conferring a genuine benefit.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.